NATURAL CAPSULES LTD.

Natural Capsules Ltd has announced that the cut-off date, also known as the record date, for its upcoming Extraordinary General Meeting (EGM) has been fixed for September 2nd, 2026. The EGM itself is scheduled to take place on September 9th, 2026. This announcement serves to inform shareholders of the specific date by which they must be registered to be eligible to attend and vote at the EGM. The company has formally communicated this record date to relevant authorities and stakeholders for their records.

Natural Capsules Ltd has announced an Extraordinary General Meeting (EGM) to be held on September 9, 2026, to approve the issuance of 1,25,000 equity shares at ₹160 per share, totaling ₹2 crore. This preferential allotment is to Mr. Sunil Laxminarayan Mundra, a promoter. The relevant date for determining the issue price is August 10, 2026. The meeting will be conducted via video conference, and the notice has been filed with the stock exchanges and uploaded on the company's website.

Natural Capsules Ltd announced that Mr. Pramod Kasat has resigned as an Independent Director from its material unlisted subsidiary, Natural Biogenex Private Limited. The resignation is effective from August 17, 2026. The company cited 'Professional Commitments' as the reason for his departure. This change pertains to the governance structure of the subsidiary and is disclosed as per SEBI regulations.

Natural Capsules Ltd announced the approval of its unaudited consolidated and standalone financial results for the quarter ended June 30, 2026. The Board of Directors also approved a preferential issue of up to 1,25,000 equity shares and 5,00,000 convertible warrants to promoter group entities at an issue price of ₹160 per share/warrant. The company is also proceeding with the draft notice for an Extra Ordinary General Meeting to seek member approval for these issuances. M/S Deepak Sadhu has been appointed as the Scrutinizer for the e-voting process.

Natural Capsules Limited announced its unaudited financial results for the quarter ended June 30, 2026. The company reported revenue of ₹48.71 Cr and a Profit After Tax (PAT) of ₹5.74 Cr. The Executive Director highlighted a strong operational quarter for the capsules business, with sustained demand and improved realisations. Challenges included a temporary disruption from a new ERP system and a mixed picture for the API business due to geopolitical uncertainty and currency headwinds. The company is optimizing HPMC capacity by converting lines to gelatine and progressing on API contract manufacturing and regulatory milestones. Demand trends remain firm for Q2FY27.

Natural Capsules Ltd's material unlisted subsidiary, Natural Biogenex Private Limited, has appointed Mr. K. H. Honneshaiah as its new Chief Operating Officer. Mr. Honneshaiah brings 36 years of extensive experience in operations and manufacturing leadership within the regulated pharmaceutical sector, including API, polymers, and peptides. His background encompasses scaling pharma plants, building greenfield capacity, and driving profitable growth, indicating a strategic move to strengthen operational capabilities within the subsidiary.

Natural Capsules Ltd's Board of Directors convened on August 12, 2026, approving the unaudited consolidated and standalone financial results for the quarter ended June 30, 2026. The board also approved a preferential issue of up to 1,25,000 equity shares and 5,00,000 warrants to the promoter group. The issue price for both shares and warrants is set at ₹160 per unit. The company also approved the draft notice for an Extra Ordinary General Meeting to be held on September 9, 2026, and appointed a scrutinizer for the e-voting process.

Natural Capsules Ltd has announced that its Board of Directors meeting, originally scheduled for August 12, 2026, to approve unaudited financial results for Q1 FY27, will now also consider a proposal for raising funds. The fund-raising could be through equity shares, convertibles, or other eligible securities on a preferential basis, subject to regulatory and shareholder approvals. The trading window for designated persons and their relatives remains closed from July 1, 2026, until 48 hours after the declaration of the financial results.

Natural Capsules Ltd has announced a Board of Directors meeting scheduled for August 12, 2026. The primary agenda is to consider and approve the unaudited consolidated and standalone financial results for the quarter ended June 30, 2026. Concurrently, the company has informed that the trading window for designated persons and their immediate relatives will remain closed from July 1, 2026, until 48 hours after the declaration of these financial results, in compliance with SEBI regulations.

Natural Capsules Ltd's material unlisted subsidiary, Natural Biogenex Private Limited, has approved the allotment of 9,46,305 equity shares through a Rights Issue. This allotment, valued at ₹94,63,050, was approved at a Board Meeting held on July 31, 2026, following an initial approval on July 10, 2026. The shares have a face value of ₹10 each and are issued for cash at par.